title: Mesenchymal status of lymphatic endothelial cell: enlightening treatment of lymphatic malformation.
abstract: In contrast to blood capillaries, lymphatic capillaries in peripheral tissues are composed of a single-cell layer of lymphatic endothelial cells (LECs) without a covering of mural cells. However, in lymphatic malformations, the enlarged lymphatic vessels were covered with mural cells. This study aimed to understand the molecular mechanism of differences between human dermal lymphatic endothelial cells (HDLECs) and human umbilical vein endothelial cells (HUVECs) and to determine the changes of LECs in the pathological condition of lymphatic malformation. Results showed that HDLECs exhibited lower expression of endothelial proteins, including VE-cadherin and CD31, than HUVECs; HDLECs also showed higher expression of mesenchymal proteins, including α-SMA, SM22α, calponin, and epithelial mesenchymal transition-related transcription factor Slug, than HUVECs. Likewise, HDLECs displayed higher permeability and weaker recruitment of SMCs than HUVECs; HDLECs also exhibited low PDGF-BB expression. TGF-β2 treatment and FGF2 depletion enhanced mesenchymal marker expression with increased permeability and reduced SMC recruitment. By contrast, Slug depletion in HDLECs enhanced VE-cadherin expression, inhibited α-SMA expression, decreased permeability, and enhanced PDGF-BB expression. These results suggested that HDLECs were in a mesenchymal status, which contributed to their functions and might determine their identities. Our data also revealed that miR143/145 was implicated in the mesenchymal status of HDLECs. In lymphatic malformations (LMs) treated with OK-432 sclerotherapy, immunohistochemistry results showed that Prox1 expression was reduced and mural cell investment was increased; these results indicated that LECs lost their mesenchymal status after OK-432 treatment was administered. The decreased mesenchymal status of LECs in LMs may induce dilated vessel constriction, which could be the mechanism of OK-432 sclerotherapy.
authors.affiliation: The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education China.
authors.forename: Xu
authors.initials: X
authors.lastname: Cai
authors.affiliation: The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education China ; Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University Wuhan 430079, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.affiliation: The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education China ; Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University Wuhan 430079, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
authors.affiliation: The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education China.
authors.forename: Rui-Fang
authors.initials: RF
authors.lastname: Li
authors.affiliation: Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University Wuhan 430079, China.
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Sun
authors.affiliation: The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education China ; Department of Oral and Maxillofacial Surgery, School & Hospital of Stomatology, Wuhan University Wuhan 430079, China.
authors.forename: Yi-Fang
authors.initials: YF
authors.lastname: Zhao
keywords: Lymphatic endothelial cell; endothelial-mesenchymal transition; lymphatic malformation; permeability; sclerotherapy